Tirzepatide (GIP/GLP-1) dual agonist research peptide
Tirzepatide is a synthetic 39-amino-acid peptide studied as a dual agonist of the GIP and GLP-1 receptors. Snowman stocks it as lyophilized powder in eight vial sizes: 5, 10, 15, 20, 30, 40, 60 and 120mg. Pick a size to see that vial's photos. Lab research only, never for people. Seen it called Tirz, GLP-2 or "the Mounjaro peptide"? Our Sema, Tirz and Reta name decoder lines up every alias.
Pick a vial size
- 5mg $25.00 USD
- 10mg $35.00 USD
- 15mg $45.00 USD
- 20mg $50.00 USD
- 30mg $75.00 USD
- 40mg $95.00 USD
- 60mg $140.00 USD
- 120mg $240.00 USD
Every fill, at a glance
Two receptors, one peptide
Tirzepatide is a single peptide that activates both the glucose-dependent insulinotropic polypeptide (GIP) receptor and the GLP-1 receptor, two hormones released from the intestine. That makes it a dual GIP/GLP-1 receptor agonist[1]. Retatrutide adds a third target, the glucagon receptor; see the retatrutide family page.
- FDA Approves New Medication for Chronic Weight Management. U.S. Food and Drug Administration press announcement, Nov 8, 2023. https://www.fda.gov/news-events/press-announcements/fda-approves-new-medication-chronic-weight-management